Pulmonary hypertension in congenital heart disease

Pulmonary hypertension is defined as a mean pulmonary arterial pressure ≥25 mmHg. We focus on its relevance in congenital heart disease, reviewing pathophysiology, diagnosis and management. Pulmonary hypertension is a relatively common complication of congenital heart disease, with adult prevalence between 5 and 10%. A multifactorial cause is recognized, relating to the size and nature of cardiac defect as well as environmental and genetic factors. More complex disease is increasingly recognized rather than pure Eisenmenger complex. Remodeling of the pulmonary vascular bed causes increased pulmonary vascular resistance diagnosed by a collection of investigations including echocardiography, exercise testing, cardiac catheterization, MRI and CT scanning. Management employs disease-modifying medications which are now used with increasing benefit.

• Publication year

  2018

• Venue

  Future Cardiology

• Publication date

  2018-05-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fca-2017-0065PMID 29792339PMCID 6136120
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disease

  2020cited by this paper
• Diagnostic accuracy of echocardiography combined with chest CT in pulmonary hypertension

  2018cited by this paper
• Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

  2017cited by this paper
• Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome

  2017cited by this paper
• Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.

  2017cited by this paper
• Multimodality imaging in congenital heart disease-related pulmonary arterial hypertension

  2016cited by this paper
• Echocardiographic correlates of severe pulmonary hypertension in adult patients with ostium secundum atrial septal defect

  2016cited by this paper
• Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

  2016cited by this paper
• Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

  2016cited by this paper
• Lung function in pulmonary hypertension.

  2015cited by this paper
• Cellular and molecular basis of RV hypertrophy in congenital heart disease

  2015cited by this paper
• Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension

  2015cited by this paper
• 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

  2015cited by this paper
• Nitric oxide

  2015cited by this paper
• Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients.

  2015cited by this paper
• Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy: The EURO-MR Study

  2014cited by this paper
• Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience

  2014cited by this paper
• Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.

  2014cited by this paper
• Predicting outcome after Fontan palliation: a single-centre experience, using simple clinical variables

  2014cited by this paper
• Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome.

  2013cited by this paper
• Patent Ductus Arteriosus Stenting (Transcatheter Potts Shunt) for Palliation of Suprasystemic Pulmonary Arterial Hypertension: A Case Series

  2013cited by this paper
• Riociguat for the treatment of pulmonary arterial hypertension.

  2013cited by this paper
• Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

  2013cited by this paper
• Pulmonary hypertension due to left heart diseases.

  2013cited by this paper
• Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry

  2012cited by this paper
• Iron deficiency is associated with adverse outcome in Eisenmenger patients.

  2011cited by this paper
• The Fontan circulation: who controls cardiac output?

  2010cited by this paper
• A noninvasive algorithm to exclude pre-capillary pulmonary hypertension

  2010cited by this paper
• Definition, Classification, and Epidemiology of Pulmonary Arterial Hypertension

  2009cited by this paper
• Tadalafil Therapy for Pulmonary Arterial Hypertension

  2009cited by this paper
• Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

  2008cited by this paper
• Molecular pathogenesis of pulmonary arterial hypertension.

  2008cited by this paper
• Eisenmenger’s syndrome:A review of the pathophysiology and therapeutic options

  2008cited by this paper
• Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry.

  2007cited by this paper
• Pulmonary Vascular Disease in Adults With Congenital Heart Disease

  2007cited by this paper
• Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease

  2006cited by this paper
• Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

  2006cited by this paper
• Pulmonary arterial hypertension

  2006cited by this paper
• Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.

  2005cited by this paper
• Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication

  2005cited by this paper
• Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease.

  2004cited by this paper
• Prostanoid therapy for pulmonary arterial hypertension.

  2004cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease

  2004cited by this paper
• Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension.

  2004cited by this paper
• Pulmonary arterial hypertension.

  2004cited by this paper
• Clinical classification of pulmonary hypertension.

  2004cited by this paper
• Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

  2004cited by this paper
• Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger’s syndrome: a clinical dilemma

  2004cited by this paper
• Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension.

  2001cited by this paper
• Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

  2001cited by this paper
• Nocturnal oxygen therapy in patients with the Eisenmenger syndrome.

  2001cited by this paper
• Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

  2000cited by this paper
• Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.

  1999cited by this paper
• Determinants of survival and length of survival in adults with Eisenmenger syndrome.

  1999cited by this paper
• Eisenmenger syndrome. Factors relating to deterioration and death.

  1998cited by this paper
• Prevention of bacterial endocarditis. Recommendations by the American Heart Association.

  1997cited by this paper
• Prevention of bacterial endocarditis. Recommendations by the American Heart Association.

  1997cited by this paper
• Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease

  1996cited by this paper
• An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

  1992cited by this paper
• Ultrastructural findings in lung biopsy material from children with congenital heart defects.

  1980cited by this paper
• Surgery of ventricular septal defect and pulmonary vascular resistance

  1970cited by this paper
• Incidence of Bacterial Endocarditis in Ventricular Septal Defects

  1966cited by this paper

• Murine Aortopulmonary Shunt Model of Flow-Driven Pulmonary Hypertension.

  2026cites this paper
• Predictive value of creatine kinase-MB in newborns with congenital heart disease

  2025cites this paper
• Fibulin 5 mediates pulmonary artery smooth muscle cell dysfunction and vascular remodelling in congenital heart disease associated pulmonary arterial hypertension via TGF-β1/PI3K/AKT signalling

  2025cites this paper
• Pressure Points: Endothelial Responses to Shear Stress and Pressure in Health and Pulmonary Arterial Hypertension

  2025cites this paper
• Pulmonary vasomodulators in adults with repaired pulmonary atresia with ventricular septal defect: Single-center experience and review of literature.

  2025cites this paper
• Consequences of Right Heart Disease for Cardiac Electrophysiology and Arrhythmias: Cellular and Structural Mechanisms

  2025cites this paper
• Growth Failure in Children with Congenital Heart Disease

  2025cites this paper
• Smooth muscle Cxcl12 contributions to vascular remodeling in flow and hypoxia-induced pulmonary hypertension

  2025cites this paper
• Pulmonary hypertension aetiologies in different parts of the world

  2025cites this paper
• Predictors of Mortality Among Patients With Opioid Use Disorder: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database

  2025cites this paper
• Airway Anomalies Predict Risk of Pediatric Pulmonary Hypertension

  2025cites this paper
• Group D of pulmonary arterial hypertension and its relationship to congenital heart disease: Is there a non-invasive way to predict the unpredictable?

  2025cites this paper
• BMPR-II, caspase-3, HIF-1α, and VE-cadherin profile in Down syndrome children with and without congenital heart disease and pulmonary hypertension

  2025cites this paper
• The Risk of Hemorrhage and Shunt Occlusion After Tonsillectomy in a Glenn Circulation Patient With Blalock-Taussig Shunt Dependence: A Case Report

  2025influential citation
• Deep Learning Approach for Predicting Cardiac Septal Defects Using Echocardiography

  2025cites this paper
• The utility of cardiac-gated computed tomography in diagnosing a reverse patent ductus arteriosus in a dog with a concurrent intracardiac right-to-left shunt.

  2024cites this paper
• Survival prospects of pulmonary arterial hypertension associated with congenital heart disease: Insights from the HOPE registry.

  2024cites this paper
• Significance of serum lncRNA XIST in chronic obstructive pulmonary disease and its progression to pulmonary heart disease

  2024cites this paper
• Smooth muscle Cxcl12 activation is associated with vascular remodeling in flow-induced pulmonary hypertension

  2024cites this paper
• Serotonin Signaling Disruption: Technological Advances in Detecting its Role in Pediatric Pulmonary Hypertension associated with Congenital Heart Defects

  2024cites this paper
• Navigating Pediatric Cor Pulmonale: A Comprehensive Review of Diagnosis and Management

  2024cites this paper
• Association of nurse-mother partnerships with parenting stress and family resilience among South Korean mothers of children with congenital heart disease.

  2024cites this paper
• Congenital Heart Defects and Concurrent Diagnoses in Influenza Hospitalization in the Pediatric Health Information System Study, 2004–2019

  2024cites this paper
• Impact of Pulmonary Artery Banding in Patients with Congenital Heart Disease and Pulmonary Hypertension

  2024cites this paper
• Identifying Key Biomarkers in Pediatric Pulmonary Hypertension: An Investigative Approach

  2024influential citation
• Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions.

  2024cites this paper
• Utility of Balloon Occlusion Testing in Determining Fontan Suitability Among Patients with Elevated Pulmonary Artery Pressure and Additional Antegrade Pulmonary Blood Flow

  2024cites this paper
• Paediatric pulmonary hypertension due to congenital heart disease in non-cardiac surgery: Anaesthetic implications

  2024cites this paper
• Therapeutic effects of treat and repair strategy in pediatric patients with pulmonary arterial hypertension and simple congenital heart defects

  2024cites this paper
• piRNAs as emerging biomarkers and physiological regulatory molecules in cardiovascular disease.

  2024cites this paper
• Evaluation of the relationship between estimated right atrial pressure and fibrosis-4 index in patients with congenital heart disease

  2024cites this paper
• Real-world diagnostic landscape and incidence of pulmonary hypertension in adult congenital heart disease patients using administrative claims data in Japan

  2024cites this paper
• Severe Pulmonary Hypertension From Combined Ventricular Septal Defect and Rheumatic MIitral Valve Disease: A Case Report and Literature Review

  2024cites this paper
• Blockade of ZFX Alleviates Hypoxia-Induced Pulmonary Vascular Remodeling by Regulating the YAP Signaling

  2024cites this paper
• Effect of face mask on pulmonary artery pressure during echocardiography in children and adolescents

  2024cites this paper
• Sinus venosus adaptation models prolonged cardiovascular disease and reveals insights into evolutionary transitions of the vertebrate heart

  2023cites this paper
• High throughput mutation screening of cardiac transcription factor GATA4 among Tanzania children with congenital heart diseases

  2023cites this paper
• Implantable Triboelectric Nanogenerators for Self-Powered Cardiovascular Healthcare.

  2023cites this paper
• Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

  2023cites this paper
• Inflammation and DKK1-induced AKT activation contribute to endothelial dysfunction following NR2F2 loss.

  2023cites this paper
• A pneumonectomy model to study flow-induced pulmonary hypertension and compensatory lung growth

  2023cites this paper
• Integrating mechanical cues with engineered platforms to explore cardiopulmonary development and disease

  2023cites this paper
• Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD

  2022cites this paper
• A Risk Prediction Model of Serious Adverse Events After Cardiac Catheterization for Chinese Adults Patients with Moderate and Severe Congenital Heart Disease

  2022cites this paper
• Analysis of healthcare-associated infection in patients with pulmonary arterial hypertension associated with congenital heart disease in PICU: Evidence from a tertiary hospital in western China

  2022cites this paper
• CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension

  2022cites this paper
• The Effects of Sequential Ventilation Therapy on Blood Gas Indexes, Pulmonary Function Indexes, Clinical Efficacy, and Safety in Patients with Severe Cor Pulmonale

  2022cites this paper
• Inhaled Milrinone via HFNC as a Postextubation Cardiopulmonary Elixir: Case Series and Review of Literature

  2022cites this paper
• Transgelin exacerbates pulmonary artery smooth muscle cell dysfunction in shunt‐related pulmonary arterial hypertension

  2022cites this paper
• Research Status of Pulmonary Hypertension in Plateau Area

  2022cites this paper
• Progressive Dyspnea in a Woman with Congenital Heart Disease and Pulmonary Arterial Hypertension.

  2022cites this paper
• Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics

  2022cites this paper
• The Association between NTproBNP Biomarker Levels and Clinical Symptoms of Cardiac Septal Defects in Children

  2022cites this paper
• Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension

  2022cites this paper
• Identification of differential microRNAs and messenger RNAs resulting from ASXL transcriptional regulator 3 knockdown during during heart development

  2022cites this paper
• Simulation of Cardiac Flow under the Septal Defect Based on Lattice Boltzmann Method

  2022cites this paper
• Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders

  2021cites this paper
• Promising Nutritional Fruits Against Cardiovascular Diseases: An Overview of Experimental Evidence and Understanding Their Mechanisms of Action

  2021cites this paper
• Demographics and Risk Factors of Pediatric Pulmonary Hypertension Readmissions

  2021cites this paper
• The diagnostic and prognostic role of amino-terminal pro-brain type natriuretic peptides in pediatric cardiac diseases and pulmonary hypertension

  2021cites this paper
• Causes of Death in Infants and Children with Congenital Heart Disease

  2021cites this paper
• The microbiome’s relationship with congenital heart disease: more than a gut feeling

  2021cites this paper
• Pulmonary artery banding in patients with functional single ventricle associated with pulmonary hypertension

  2021cites this paper
• Management of reproductive health in patients with pulmonary hypertension.

  2020cites this paper
• Pulmonary hypertension associated with congenital heart disease; clinical decision scenario

  2020cites this paper
• Portopulmonary Hypertension: From Bench to Bedside

  2020cites this paper
• Nestin represents a potential marker of pulmonary vascular remodeling in pulmonary arterial hypertension associated with congenital heart disease.

  2020cites this paper
• A New TBX5 Loss-of-Function Mutation Contributes to Congenital Heart Defect and Atrioventricular Block.

  2020cites this paper
• Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry

  2020cites this paper
• Heart failure in adult congenital heart disease: tetralogy of Fallot

  2020cites this paper
• Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases

  2019cites this paper
• MicroRNA-204 as an Indicator of Severity of Pulmonary Hypertension in Children with Congenital Heart Disease Complicated with Pulmonary Hypertension

  2019cites this paper
• Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease

  2019cites this paper
• Reverse Remodeling of Pulmonary Arterioles After Pulmonary Artery Banding in Patients ≥ 2 Years Old with Severe Pulmonary Arterial Hypertension and Congenital Heart Disease

  2019cites this paper
• Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.

  2017cites this paper